20-074 - A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaStatus: open
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma
Treatment for Liver Cancer
This clinical trial is for patients who have been diagnosed with Locoregional Hepatocellular Carcinoma (HCC). The study evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy.
SponsorsThis trial is sponsored by Astra Zeneca.
Interested in Clinical Trial?
Providers Associated With This Trial
- Moh'd Khushman, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology
- Sachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology
- Osama Abdul-Rahim, M.D.Interventional RadiologistAssistant Professor of Radiology